Managing Acyvir resistance starts with confirming the problem. Genotypic testing of the viral DNA polymerase can identify specific mutations, while therapeutic drug monitoring helps adjust dose for kidney function. If a mutation is confirmed, clinicians typically switch to higher‑dose Acyclovir, add oral valacyclovir, or use alternative agents such as famciclovir or penciclovir. For patients with severe renal impairment, dose reduction and hydration are critical to avoid toxicity. In practice, the semantic triple Acyvir resistance requires viral DNA polymerase mutation guides the choice of an alternative antiviral, and the triple Acyvir resistance encompasses herpes virus infections reminds providers to treat the underlying infection aggressively. Below you’ll find a curated set of articles that dive deeper into drug interactions, dosing strategies, and patient‑focused advice, giving you a toolbox to handle resistance when it shows up.